Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.27 -4.20 (-7.72%)

Streaming Delayed Price Updated: 10:31 AM EDT, Apr 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

45 46 Next >

GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo? ↗

May 12, 2023

GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm

Via Benzinga

Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗

May 12, 2023

The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have

Via Benzinga

GSK Trims Stake On Consumer Business Spin Off, Raises £804M ↗

May 12, 2023

GSK Plc (NYSE: GSK) sold 240 mi

Via Benzinga

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns ↗

May 12, 2023

The monoclonal antibody shot significantly reduced the risk of hospitalization in babies.

Via Investor's Business Daily

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

May 11, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

GSK Stock: A Value Trap or a Hidden Gem? ↗

April 27, 2023

GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy.

Via InvestorPlace

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer ↗

May 11, 2023

RSV could be the next big battleground for big pharma -- but it could soon become crowded.

Via The Motley Fool

Dividend Income Update April 2023 ↗

May 11, 2023

With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated.

Via Talk Markets

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

May 08, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

Via MarketBeat

WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns ↗

May 08, 2023

The World Health Organization ended the global emergency

Via Benzinga

GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance ↗

April 26, 2023

Via Benzinga

GSK: Add This Cheap Chip Play To Your Portfolio ↗

May 06, 2023

GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%.

Via Talk Markets

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

May 04, 2023

From HKTDC

Via ACN Newswire

A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market ↗

May 03, 2023

The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in...

Via Benzinga

US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

May 03, 2023

From GSK plc

Via Business Wire

GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line ↗

May 03, 2023

GSK won FDA approval for the first-ever RSV vaccine for older adults.

Via Investor's Business Daily

KVUE Stock: Should You Buy Into the Kenvue IPO? ↗

May 03, 2023

KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business.

Via InvestorPlace

Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says ↗

May 03, 2023

Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

May 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US ↗

April 27, 2023

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure...

Via Benzinga

Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost? ↗

April 27, 2023

The company reported lighter-than-expected declines due to Keytruda and Gardasil.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 26, 2023

Via Benzinga

3 Biotechs That Might Get Bought Out in 2023 ↗

April 26, 2023

Biotech is expected to be a hotbed of mergers and acquisitions this year.

Via The Motley Fool

Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls ↗

April 26, 2023

Both GSK and Roche experienced declining Covid-related sales in the first quarter.

Via Investor's Business Daily

Was This Acquisition a Savvy Play by This Big Pharma Stock? ↗

April 26, 2023

The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.

Via The Motley Fool

Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value ↗

April 25, 2023

Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a

Via Benzinga

April 25, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗

April 25, 2023

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

Via The Motley Fool

Second Quarter Outlook For Biotech Stocks ↗

April 25, 2023

Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.

Via Talk Markets

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

The Newspapers of New England Family

We continue to need local support from our readers

Enjoying the Concord Monitor?

CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Sign in